More precisely, circulating M30 levels correlated with markers indicating the hepatic biosynthetic capacity (e.g., international normalized ratio (INR), antithrombin III, and pseudocholinesterase), parenchymal damage (e.g., glutamate dehydrogenase (GLDH), aspartate transaminase, and alanine transaminase) and parameters indicating cholestasis (e.g., gamma-glutamyltransferase, alkaline phosphatase, and bilirubin, Figure 1(e)) as well as markers tracing renal dysfunction (e.g., creatinine, cystatin C, and glomerular filtration rate). The gene discussed is GPT; the disease is cholestasis.